PRTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Prothena Corporation PLC (PRTA) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown some positive developments, such as improved financial positioning and a recent price increase, the technical indicators and options data suggest limited immediate upside potential. Additionally, there are no strong trading signals or significant catalysts to justify an immediate buy decision.
The MACD is positive and expanding, indicating a bullish momentum. However, the RSI is neutral at 61.879, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 9.137 and 9.526, while support levels are at 8.507 and 7.876. The stock's recent price increase may face resistance near these levels.
Analysts have raised the price target to $20, citing improved liquidity and reduced cash burn.
The company received a $50M milestone payment from Novo Nordisk, strengthening its financial position.
The stock has a bearish moving average trend.
Stock trend analysis suggests a potential decline of -6.17% over the next month.
No significant hedge fund or insider trading activity to support bullish sentiment.
The company reported expected first-quarter revenues of $67.24 million, a 14.2% year-over-year increase. However, a quarterly loss of $0.13 per share is anticipated, although the consensus EPS estimate has been revised 3.6% higher.
Analysts maintain an Outperform rating with a price target raised to $20 from $19. The focus is on the company's improved liquidity and reduced cash burn, which are positive for long-term investors.
